Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 208.29

-0.3%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (13192)	1/10/1998 7:57:00 PM
From: Henry Niman	Read Replies (1) of 32384

Andy, LLY is supposed to start clinical trials on 2nd generation rexinoids this year. They have a choice of LGD1268 or the other one (LGD1324?). It's their call I believe. They may be doing some more pre-clinicals on it to decide which one should enter the clinic. As will virtually all areas targeted by the Rexinoids, the problems is too many interesting compounds. As far as Targretin in breast cancer is concerned, I think that I saw a trial somewhere in the past, but I haven't found it yet. There have been two trials started using Panretin in combination with Tamoxifen, but as you know Targretin looks like it would be a great combo with Tamoxifen, especially for PREVENTION of breast cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next